Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a strategic ...

Coming from a long line of Iowa farmers, David Savage always thought he would do research to improve crops. That dream died in college, when it became clear that any genetic tweak to a crop would take ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.

Editas Medicine is a clinical-stage drugmaker developing CRISPR-based gene therapies. So far, Editas Medicine's candidate for sickle cell disease patients is performing well in clinical trials. Editas ...

Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that ...

In a major advance, the Food and Drug Administration on Friday approved two gene therapies that target sickle cell disease, one of which is the first commercially available treatment in the United ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

Editas Medicine is transitioning from platform development to establishing itself as a key player in the commercial therapeutics market. The company's strategic priorities include fast-tracking the ...

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary gene editing technology that allows scientists to modify DNA sequences with unprecedented precision, efficiency, ...

Shares of Crispr Therapeutics CRSP and Vertex Pharmaceuticals Inc. VRTX gained ground premarket on Thursday after the companies got the world’s first regulatory authorization for a medicine based on ...

Editas Medicine is a gene-editing biotech, just like CRISPR Therapeutics. Editas has a long way to go before it'll be self-sustaining, and it might not get there. It's also going to be facing down ...